Given this, there is controversy around the standard of care for EGFRm NSCLC patients who have progressed on EGFR TKIs, with some advocating for chemotherapy alone and some advocating for chemotherapy combined with ICI therapy (79, 80). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.